Brookline Capital initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $5.65

Alliance Global Partners initiated coverage of Icecure Medical with a rating of Buy and set a new price target of $14.50

6-K - IceCure Medical Ltd. (0001584371) (Filer)

6-K - IceCure Medical Ltd. (0001584371) (Filer)

EFFECT - IceCure Medical Ltd. (0001584371) (Filer)

6-K - IceCure Medical Ltd. (0001584371) (Filer)

POS AM - IceCure Medical Ltd. (0001584371) (Filer)

6-K - IceCure Medical Ltd. (0001584371) (Filer)

6-K - IceCure Medical Ltd. (0001584371) (Filer)

F-3 - IceCure Medical Ltd. (0001584371) (Filer)

6-K - IceCure Medical Ltd. (0001584371) (Filer)

6-K - IceCure Medical Ltd. (0001584371) (Filer)

ProSense® cryoablation offers the choice of a minimally invasive outpatient procedure that destroys tumors by freezing without surgical removal of breast tissue  First new innovation in the local treatment of early-stage, low-risk breast cancer in decades and only medical device to be granted FDA marketing authorization for breast cancer treatment Offers efficacy and safety similar to standard of care lumpectomy, with excellent cosmetic results and patient satisfactionCompany conference call to be held at Monday, October 6 at 8:30 AM Eastern TimeCAESAREA, Israel, Oct. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a mi

ProSense® is the first and only medical device to be granted FDA marketing authorization for the local treatment of breast cancer Major advancement and new paradigm in breast cancer care as a simple, minimally invasive out-patient procedure Initial reimbursement under the CPT III code which covers $3,800 of facility costs, with additional reimbursement coverage expectedU.S. sales and distribution team ready to drive sales of ProSense® systems and disposable probes—supporting medical community and patients looking for a new minimally invasive option to lumpectomy Enthusiastic response from top U.S. breast surgeons and radiologistsConference call to be held Monday, October 6 at 8:30AM Eastern

The invention is designed to improve cryoprobe extraction, further reducing risk of tissue trauma, leading to lower costs and improved patient experience XSense™ System with Cryoprobes recently received regulatory approval in the U.S. and Israel CAESAREA, Israel, Sept. 18, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent titled "Cryoprobe". "Our industry-leading liquid-nitrogen-based cryoablation pla

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August 2025[1] signaled the recent wave of regulatory momentum behind next-generation therapies. Meanwhile, advanced treatment platforms are achieving complete tumor elimination in clinical trials across multiple cancer types[2]. These developments position Oncolytics Biotech Inc. (NASDAQ:ONCY), Anixa Biosciences, Inc. (NASDAQ:ANIX), IceCure Medical Ltd. (NASDAQ:ICCM), ImmunityBio, Inc. (NASDAQ:IBRX), and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Industry analysts at Exactitude Consultancy project the can

Approved for a broad range of indications including in gynecology, oncology and general surgery CAESAREA, Israel, Sept. 15, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it has received regulatory approval from the Medical Device Division of Israel's Ministry of Health ("AMAR") for its next-generation single cryoprobe cryoablation system, the XSense™ System and CryoProbes. As of mid-2024, XSense™ and its cryoprobes have also received regulatory clearance in the United States from the U.S.

Article published in European Journal of Surgical Oncology focused on cosmetic outcomes and patient satisfaction reports 95% of patients were very satisfied or satisfied with thermal ablation Article published in Radiology demonstrated that cryoablation with ProSense® achieved the highest complete ablation rate compared to alternatives with no adverse events CAESAREA, Israel, Sept. 8, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced two publications reporting positive results for the ProSense®

Independent study reports pain scores declined from a median of 8 on a scale of 0-10 to a median of 0 for patients who had ProSense® cryoablation procedures ProSense® is FDA cleared and approved in the European Union for gynecological indications CAESAREA, Israel, Sept. 4, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced encouraging findings from a recently published, independently conducted study evaluating the efficacy and safety of personalized percutaneous single-probe liquid-nitroge

$10 million two-times over-subscribed rights offering creates cash runway to anticipated FDA marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer Conference call to be held today at 11:00 am Eastern Time CAESAREA, Israel, Aug. 13, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the six months ended June 30, 2025. During the second quarter of 2025, IceCure concluded a productive meeting with the leadership

CAESAREA, Israel, Aug. 6, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced  it will issue a press release with its financial and operational results as of and for the six months ended June 30, 2025 before the Nasdaq Stock Market opens on Wednesday, August 13, 2025. The Company will also discuss such results and other corporate developments on a conference call at 11:00 a.m. EDT on the same day. Conference call & webcast info:Wednesday, August 13, 2025, at 11:00 am EDTUS: 1-888-407-2553Isr

CAESAREA, Israel, July 29, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that the subscription period of its previously announced rights offering (the "Rights Offering") expired at 5:00 p.m., Eastern Time, on July 28, 2025. As previously disclosed, the Company distributed to all holders of record of the Company's ordinary shares, no par value per share ("Ordinary Shares") as of 5:00 p.m., Eastern Time, on July 9, 2025 (the "Record Date"), at no charge, non-transferable subscription righ

Mr. Shad Good brings nearly 20 years of medical device sales and leadership experience, including as U.S. Senior Director of Sales at a global leader in minimally invasive breast diagnostic and therapeutic systemsImmediate responsibility is to build out the sales infrastructure as the Company awaits the FDA response to its regulatory filing for early-stage low risk breast cancer in patients who are at high risk for surgery as well as the FDA's response to the final ICE3 results which are due in 2024 CAESAREA, Israel, Aug. 28, 2023 /PRNewswire/ -- IceCure Medical Ltd. ("IceCure" or the "Company") (NASDAQ:ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology tha

Galit Bar Malik promoted to VP of Operations and Service CAESAREA, Israel, Dec. 6, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the appointment of Vincent Chun Hung Chan to serve as an independent director on the Company's board of directors. Mr. Chan has been a private equity executive for the past three decades, managing and leading more than 80 investment projects supporting company growth via funding and synergistic mergers and acquisitions. Since March 2021, he has been the Director of Samena Capital, a prin

CAESAREA, Israel, Nov. 29, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the appointment of Mrs. Merav Nir Dotan to the new position of Vice President, Human Resources. Mrs. Nir Dotan has over two decades of experience in human resources and organizational management. "As the company continues to evolve, we believe investing in our Human Resources function commensurate with an investment in human capital so Mrs. Nir Dotan's appointment is key," stated Eyal Shamir, Chie

ProSense® cryoablation offers the choice of a minimally invasive outpatient procedure that destroys tumors by freezing without surgical removal of breast tissue  First new innovation in the local treatment of early-stage, low-risk breast cancer in decades and only medical device to be granted FDA marketing authorization for breast cancer treatment Offers efficacy and safety similar to standard of care lumpectomy, with excellent cosmetic results and patient satisfactionCompany conference call to be held at Monday, October 6 at 8:30 AM Eastern TimeCAESAREA, Israel, Oct. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a mi

$10 million two-times over-subscribed rights offering creates cash runway to anticipated FDA marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer Conference call to be held today at 11:00 am Eastern Time CAESAREA, Israel, Aug. 13, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the six months ended June 30, 2025. During the second quarter of 2025, IceCure concluded a productive meeting with the leadership

CAESAREA, Israel, Aug. 6, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced  it will issue a press release with its financial and operational results as of and for the six months ended June 30, 2025 before the Nasdaq Stock Market opens on Wednesday, August 13, 2025. The Company will also discuss such results and other corporate developments on a conference call at 11:00 a.m. EDT on the same day. Conference call & webcast info:Wednesday, August 13, 2025, at 11:00 am EDTUS: 1-888-407-2553Isr

Recently finalized and delivered proposed post market study plan to the FDA; Awaiting marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer Continues to see rising interest in North America for ProSense® Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, May 28, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the three months ended March 31, 2025. IceCure delivered its proposed post

CAESAREA, Israel, May 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the three months ended March 31, 2025 before the Nasdaq Stock Market opens on Wednesday, May 28, 2025. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day. Conference call & webcast info:Wednesday, May 28, 2025, at 10:00 am EDTUS: 1-888-407-2553Is

Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through 33 peer-reviewed journals and medical conferences during 2024 Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, March 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the twelve months ended December 31, 2024. IceCure continues to engage with the U.S. Food and Drug Admin

CAESAREA, Israel, March 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2024 before the Nasdaq Stock Market opens on Thursday, March 27, 2025. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day. Conference call & webcast info: Thursday, March 27, 2025, at 10:00 am EDTUS: 1-888-4

FDA Marketing Authorization Decision on Early Stage-Low Risk Breast Cancer Expected in Q1 2025 Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, Nov. 26, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the nine months ended September 30, 2024. Sales of ProSense® consoles and disposable probes increased by 36%. Gross profits increased by 41%, while non-GAAP gross profits grew by 104%. Gross margins increased to 43%, while non-GAAP gr

CAESAREA, Israel, Nov. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release with its financial and operational results as of and for the nine months ended September 30, 2024 before the Nasdaq Stock Market opens on Tuesday, November 26, 2024. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EST on the same day. Conference call & webcast info: Tuesday, November 26, 2024, at 10:00 am EST US: 1-888-407-2553 Israel/Inte

Near-term regulatory and operating catalysts have potential to accelerate adoption of ProSense® for treatment of early-stage, low risk breast cancer Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel, Aug. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the six months ended June 30, 2024. Significant Near and Short Term Value Enhancing Catalysts U.S. Food and Drug Administration ("FDA") Medical Device Advisory Committee expected

SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)

SC 13G - IceCure Medical Ltd. (0001584371) (Subject)

SC 13G/A - IceCure Medical Ltd. (0001584371) (Subject)